PRODIGE 4 / ACCORD 11
2011
FOLFIRINOX in Metastatic Pancreatic Cancer
In 342 patients with metastatic pancreatic adenocarcinoma, ECOG 0–1, age ≤75, FOLFIRINOX improved overall survival compared with gemcitabine.
Result
Efficacy: Overall survivalHR 0.57
Below 1 favours FOLFIRINOX, above 1 favours gemcitabine.
Event rates FOLFIRINOX 11.1 vs gemcitabine 6.8 months
Also reported: PFS HR 0.47; ORR 31.6% vs 9.4%; more grade 3/4 toxicity but better QoL maintenance.
- Subtopic
- Metastatic pancreatic
- Design
- Phase 2/3 RCT
- Relevance
- Important: one of several pillars.
- Source
- Conroy T, et al. N Engl J Med. 2011;364(19):1817-1825.doi 10.1056/NEJMoa1011923
Discussion & critique
Most active regimen in fit metastatic-pancreatic patients; later extended to the adjuvant setting (PRODIGE 24). Reserve for ECOG 0–1.